Securities notice · Vesalius Longevity Labs is not yet a reporting issuer. The proposed reverse takeover transaction is subject to regulatory and shareholder approvals. Nothing on this site constitutes an offer to sell or solicitation to buy securities.
We are building the leading peptide and longevity brand, globally — and one of the first public companies in the sector. Vesalius is a longevity science and regenerative health platform focused on peptides, biologics, preventative healthcare, and performance optimization. The Company operates a scalable B2Doctor2Consumer ecosystem designed to support healthcare providers, telehealth infrastructure, product fulfillment, and advanced longevity therapeutics across global markets.
Vesalius' expanding ecosystem includes peptide therapeutics, regenerative medicine initiatives, royalty-generating biologics partnerships, and advanced provider enablement technologies designed to support the future of personalized health and wellness.
Global Wellness Economy estimated at US$6.3 trillion with projected growth of 7.3% annually over the next five years. Global peptide therapeutics market projected to grow from approximately US$43 billion to US$106 billion by 2033.
One of the first publicly traded companies focused exclusively on longevity science.
B2Doctor2Consumer distribution platform serving licensed healthcare providers. Royal Longevity subsidiary holds a revenue and royalty-generating agreement tied to MuseCell Innovations' licensed U.S. labs.
Doctor distribution network across North America, Europe, UAE, Asia Pacific, and Latin America.
Active expansion into global markets with provider onboarding and strategic partnerships underway.
Peptual portfolio, Telemedicine, MCI collaboration (Peptual Skin x DEZAWA MUSECELLS).
Board, scientific advisors, and management bring expertise across healthcare, biotech, fintech, consumer platforms, and public markets.
Building the leading peptide and longevity brand, globally — and one of the first public companies in the sector.
This section may contain forward-looking information within the meaning of applicable Canadian securities laws. Such statements reflect current expectations and are subject to risks, uncertainties, and other factors that could cause actual results to differ materially. Investors are urged to read the company's public filings on SEDAR+ and to consult their own advisors. Nothing on this site constitutes an offer to sell or a solicitation to buy securities.
Full cautionary note